Cyclopharm (ASX:CYC) - Managing Director and CEO, James McBrayer
Managing Director and CEO, James McBrayer
Source: Cyclopharm
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cyclopharm (CYC) shares drop 35 per cent after the US Food and Drug Administration knocked back its drug application for Technegas
  • The healthcare stock revealed on Monday the FDA has been unable to approve its New Drug Application, while also providing a list of recommendations
  • CYC’s Managing Director and CEO says the knock back is disappointing, but he’s confident the company can address the FDA’s requirements
  • The healthcare stock is hopeful it can gain FDA approval of Technegas, which is designed to provides ventilation imaging, within another nine months
  • Company shares remain trading in the red towards the close of market, down 35.8 per cent at $1.76, with 98 cents wiped from its price in today’s session

Cyclopharm (CYC) shares dropped 35 per cent after it announced the US Food and Drug Administration (FDA) knocked back its drug application for Technegas.

The healthcare stock revealed on Monday the US FDA had been unable to approve its New Drug Application, while also providing a list of recommendations.

Most of the issue outlined by the drug body involve better defining and validating
the unique characteristics and delivery of Technegas, which was designed to provides ventilation imaging.

Commenting on the FDA’s decision, CYC Managing Director and CEO James McBrayer said it was disappointing.

“While the elements in the US FDA’s CLR letter are attainable within the required timeframe, we are disappointed with this news of the additional technical information requests,” Mr McBrayer said.

“Effectively the CLR has extended the expected approval timeframe by around nine months.”

Mr McBrayer said the company was confident it could resolve the outstanding issues raised by the FDA within that time period.

“We have complete confidence that we can address these matters and do what is required to expedite this process.

“We now have clarity as to what will satisfy the USFDA’s expectations and will commence work on the response immediately.”

Despite the reassurance, following today’s news, shares in Cyclopharm have plummeted with 98 cents wiped from the company’s share price.

It closed last Friday’s trading session at $2.74, before dropping over 35 per cent during Monday’s session.

At the close of market, CYC’s share price was down 35.8 per cent at $1.76.


CYC by the numbers
More From The Market Online
Image representing bacterial infections in the immune system

Recce reaches key dosing milestone in testing of skin infection gel

Recce Pharmaceuticals Ltd has successfully dosed 20 out of 30 participants in its Phase II trial…
Bank of England London town

Wellnex bumps first $3M payment for Pain Away into 1Q25 – when it lists in London

Wellnex Life Ltd (ASX:WNX) has unveiled its plans to defer a $2.95M payment to 360 Health…
DNA RNA therapy concept

PYC Therapeutics moves into final stage of child blindness study

PYC has been approved to escalate doses of its drug candidate VP-001, treating Retinitis Pigmentosa 11,…
AI image of a scan on kidneys

Dimerix links up with US NEPTUNE network to boost recruitment for FSGS study

Dimerix Ltd is set to partner with a key research network at the University of Michigan…